Mancia G, Stella M L, Grassi G
Cattedra di Medicina Interna, Università di Milano, Ospedale San Gerardo, Monza, Italy.
Curr Opin Cardiol. 1999 Sep;14(5):375-80. doi: 10.1097/00001573-199909000-00004.
Despite the many outstanding favorable results achieved in the treatment of hypertension, several unmet goals of antihypertensive therapy remain, such as better blood pressure control, greater protection against the organ damage associated with hypertension, better tolerability, and ultimately a more effective prevention of cardiovascular disease. These unmet goals are the reasons why new antihypertensive drugs are synthesized and tested in the clinical practice. This paper briefly mentions the goals of new antihypertensive agents and examines the main pharmacological and clinical features of new classes of antihypertensive drugs, such as angiotensin II receptor blockers, central agents, vasopeptidase inhibitors, and endothelin antagonists. The results of experimental and clinical studies with these new drugs are reviewed, emphasizing some advantages and potential disadvantages of these drugs compared with traditional antihypertensive drugs.
尽管在高血压治疗方面取得了许多显著的良好效果,但抗高血压治疗仍存在一些未实现的目标,如更好地控制血压、更强地预防与高血压相关的器官损害、更好的耐受性,并最终更有效地预防心血管疾病。这些未实现的目标是在临床实践中合成和测试新型抗高血压药物的原因。本文简要提及新型抗高血压药物的目标,并研究新型抗高血压药物类别的主要药理和临床特征,如血管紧张素II受体阻滞剂、中枢性药物、血管肽酶抑制剂和内皮素拮抗剂。综述了这些新药的实验和临床研究结果,强调了这些药物与传统抗高血压药物相比的一些优点和潜在缺点。